Table 3.
Clinical data in DCMR-neg patients
DCMR-neg patients | Patients without invasive angiography | |||||
no invasive angio | invasive angio | no event | event | |||
n = 833 | n = 90 | p† | n = 825 | n = 8 | p‡ | |
Clinical characteristics | ||||||
Age [years] | 62 ± 11 | 64 ± 11 | 0.27 | 62 ± 11 | 59 ± 10 | 0.28 |
Male, % | 62 | 72 | 0.06 | 62 | 71 | 0.61 |
Body mass index [kg/m2] | 27 ± 4 | 27 ± 4 | 0.77 | 27 ± 4 | 28 ± 6 | 0.29 |
LVEF | 58 ± 6 | 58 ± 8 | 0.31 | 58 ± 6 | 53 ± 14 | 0.76 |
Hypertension, % | 70 | 76 | 0.26 | 70 | 86 | 0.36 |
Hyperlipidemia, % | 57 | 71 | 0.01 | 57 | 86 | 0.13 |
Diabetes mellitus, % | 19 | 22 | 0.39 | 18 | 29 | 0.49 |
Smoking, % | 30 | 41 | 0.03 | 30 | 29 | 0.93 |
Family history, % | 34 | 30 | 0.49 | 34 | 14 | 0.28 |
Framingham risk score | 15 ± 11 | 16 ± 11 | 0.56 | 15 ± 11 | 18 ± 9 | 0.7 |
Known CAD, % | 32 | 58 | <0.001 | 32 | 57 | 0.15 |
Prior myocardial infarction, % | 22 | 30 | 0.11 | 30 | 71 | 0.03 |
Prior PCI, % | 25 | 52 | <0.001 | 25 | 43 | 0.38 |
Prior CABG, % | 10 | 22 | 0.001 | 10 | 29 | 0.16 |
Medication, % | ||||||
Aspirin | 60 | 87 | <0.001 | 60 | 86 | 0.25 |
Betablocker | 62 | 76 | 0.01 | 61 | 100 | 0.04 |
ACE inhibitor | 48 | 67 | 0.001 | 48 | 57 | 0.71 |
Angiotensin receptor blocker | 25 | 20 | 0.4 | 25 | 14 | 0.53 |
Calcium channel blocker | 21 | 27 | 0.28 | 21 | 14 | 0.65 |
Statin | 57 | 87 | <0.001 | 56 | 71 | 0.43 |
Diuretic | 32 | 46 | 0.02 | 32 | 29 | 0.83 |
Values are expressed as mean ± SD or %, †DCMR-pos patients with vs. without invasive coronary angiography, ‡DCMR-pos patients with vs. without coronary stenosis